Temsirolimus, a distinct mTOR inhibitor analogous to everolimus, was recognized in 2007 as an advanced treatment for renal cell carcinoma.36Temsirolimus additionally binds to FK506-binding proteins and the subsequent compound binds to mTOR and inhibits its effect on G1 phase progression of the cell cycle, cell growth, and proliferation. This evidence concerns the gene MTOR and hereditary clear cell renal cell carcinoma.